Taiwan's TLC Reports Positive Data on Long-Acting Steroid for Arthritis

TLC (Taiwan Liposome Company) reported positive top-line results from the Phase I/II trial of TLC599, a sustained release corticosteroid. From baseline to week 12, the candidate demonstrated a trend of clinically meaningful reduction in pain among patients with arthritis of the knee, using several widely-used assessments of pain. TLC explains that, for safety reasons, corticosteroids can be used only once every three months, but their beneficial effect lasts for just two weeks. TLC used its proprietary BioSeizer platform to create the sustained release formula. More details.... Stock Symbol: (TT: 4152) Share this with colleagues: // //